Therapeutic area
Immunology
Autoimmune, inflammation, and immune-modulating programs across the spin-out-to-raise crosswalk.
6,904 pre-ticker companies classified in immunology right now.
Pipeline by stage
Where these companies sit on the ladder from a first grant to an approved product. Derived from evidence in public filings, never inferred past it.
- Grant-only5,956
- Formed19
- Preclinical1
- IND-enabling0
- Phase I252
- Phase II358
- Phase III203
- Filed/Approved115
Highest momentum in immunology
Not included in your seat
Immunology is outside your seat
The counts above are public. The ranked companies, their momentum, and their dossiers in Immunology follow your seat. The free tier covers oncology; a Fund or Feed seat covers every area, and an Analyst seat can be switched to immunology from your account.
Counts are public federal records; momentum is a recency-weighted score over public filing events, shown identically to every viewer. Informational only, not investment advice. All areas · Methodology